Interestingly, a recent phase II double-blind RCT in patients with ocular hypertension or POAG found that twice daily application of topical Razuprotafib, which activates TEK receptors via vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibition, reduced IOP when given in addition to latanoprost [46]. The gene discussed is PTPRB; the disease is ocular hypertension.